Showing 8611-8620 of 9547 results for "".
- Cynosure Taps New CEOhttps://practicaldermatology.com/news/cynosure-taps-new-ceo/2461676/Nadav Tomer is Cynosure’s new chief executive officer, effective May 1, 2023. He succeeds Todd Tillemans, who will step down and will work closely with Mr. Tomer to ensure a smooth transition. "Nadav has an incredibly strong track record of operation
- Galderma Survey Debunks Filler Mythshttps://practicaldermatology.com/news/galderma-survey-debunks-filler-myths/2461668/Forty percent of people say they would discourage others from using facial injectables to reduce wrinkles or provide volume, and 34% said they believed the results of such treatments look fake and unnatural, according to a new poll sponsored by Galderma. Despite these views, the same re
- 2023 Medscape Report: Physician Salaries Rise as Gender Gap Narrowshttps://practicaldermatology.com/news/2023-medscape-report-physician-salaries-rise-as-gender-gap-narrows/2461663/Doctor salaries continue to rise as the gender gap narrows, according to the 2023 Medscape Physician Compensation Report. The largest difference for women was seen in primary care, but the disparity also narrowed within specialties, from a 36% difference i
- Survey: Gen Z and Millennial Men Fall Short on Face Washing, Skin Carehttps://practicaldermatology.com/news/survey-gen-z-and-millennial-men-fall-short-on-face-washing-skin-care/2461656/Many Gen Z and millennial men would rather going on a bad date than take care of their skin, according to a new survey conducted by OnePoll on behalf of CeraVe. In a recent survey of 2,000 men ages 18–26 and 27–42, two in five (42%) revealed they need someone to confront the
- Prior Immunotherapy May Predict Response to PD-1 Checkpoint Blockadehttps://practicaldermatology.com/news/prior-immunotherapy-may-predict-response-to-pd-1-checkpoint-blockade/2461655/Responses to PD-1 checkpoint blockade in patients with advanced melanoma depend on whether or not they had previously received CTLA-4 blockade as well as other factors, new research suggests. Their findings, based on analysis of seven data sets generated over the past decade, which incl
- Millennials, Gen Xers Not Well-Schooled on Skin Cancer Preventionhttps://practicaldermatology.com/news/millennials-gen-xers-not-well-schooled-on-skin-cancer-prevention/2461648/Millennials and Gen Xers are racked with sun regrets, a new survey shows. Just 19% of millennials and Gen Xers wear sunscreen all year, 35% used a tanning bed, and 46% regretted how long they stayed out in the sun when they were younger. This is why
- New Way to Measure Skin Barrier Function Identifiedhttps://practicaldermatology.com/news/new-way-to-measure-skin-barrier-function-identified/2461628/Scientists in Japan have devised a new way to measure skin barrier function. Most methods indirectly calculate skin barrier function using a proxy measure called transepidermal water loss (TEWL), but the dependance on a heavily controlled environment is one of the primary limitations of this
- HS Update: Studies Suggest TNF, IL-17, and JAK inhibitors May Play a Role in Treating HShttps://practicaldermatology.com/news/hs-update-studies-suggest-tnf-il-17-and-jak-inhibitors-may-play-a-role-in-treating-hs/2461627/Several new potential therapies for hidradenitis suppurativa (HS) are coming down the pike, according to research presented at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans. Acelyrin, Inc.'s Izokibep led to HiSCR response at 12 weeks, including H
- Take That SKs! DermBiont’s SM-020 Topical Gel Performs Well in Phase 2 Studyhttps://practicaldermatology.com/news/take-that-sks-dermbionts-sm-020-topical-gel-performs-well-in-phase-2-study/2461623/More than 80% of seborrheic keratosis (SK) lesions treated for 14 to 28 days with DermBiont’s SM-020 gel 1.0% had at least a one-point improvement in Physician’s lesion assessment (PLA) score at last visit, according to Phase 2 trial data presented at the
- Takeda’s TYK2 Blocker Impresses in Phase 2b PsO Studyhttps://practicaldermatology.com/news/takedas-tyk2-blocker-impresses-in-phase-2b-pso-study/2461622/Takeda’s TYK2 inhibitor TAK-279 performed well in a Phase 2b study of patients with moderate-to-severe plaque psoriasis. TAK-279 was developed by Nimbus Therapeutics and owned by Takeda. The new findings were presented at the 2023 American Academy of Dermatology (AAD) An